Tang Kevin C's Form 4 filing
Aurinia Pharmaceuticals Inc. (AUPH) · filed Dec 9, 2024
- Accession no.
- 0001415889-24-028661
- Filed
- Dec 9, 2024
- Trade date
- Dec 5-9, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $10.8M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tang Kevin CCIK 0001178579 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2024 | Common Shares | PPurchaseAcquired | +300,000 | $8.91 | +$2,673,000 | 7,529,500 | Indirect | |
| Dec 6, 2024 | Common Shares | PPurchaseAcquired | +400,000 | $9.01 | +$3,604,000 | 7,929,500 | Indirect | |
| Dec 9, 2024 | Common Shares | PPurchaseAcquired | +500,000 | $9.09 | +$4,545,000 | 8,429,500 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.